Cite
HARVARD Citation
Fowler, R. et al. (n.d.). FRI0364 Real-World Incidence of Biologic Dose Escalation and Impact on Biologic Costs Among Patients with Rheumatoid Arthritis Treated with Intravenous Agents Abatacept, Infliximab or Tocilizumab. Annals of the rheumatic diseases. p. 558. [Online].